Michael F. Marino III - 01 Jun 2025 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Signature
/s/ Louise Kooij by Power of Attorney from Michael F. Marino III
Issuer symbol
NAMS
Transactions as of
01 Jun 2025
Net transactions value
$0
Form type
4
Filing time
03 Jun 2025, 17:02:34 UTC
Previous filing
03 Jun 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Marino Michael F III Chief Legal Officer and Corporate Secretary C/O NEWAMSTERDAM PHARMA COMPANY N.V., GOOIMEER 2-35, NAARDEN, NETHERLANDS /s/ Louise Kooij by Power of Attorney from Michael F. Marino III 03 Jun 2025 0001502700

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NAMS Ordinary Shares Award +55,000 55,000 01 Jun 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NAMS Option (right to buy) Award $0 +315,000 $0.000000 315,000 01 Jun 2025 Ordinary Shares 315,000 $18.11 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs"), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date.
F2 Each RSU was granted on June 1, 2025 for no consideration.
F3 25% of the shares underlying the option will vest on June 1, 2026, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

Remarks:

Chief Legal Officer and Corporate Secretary